Skip to main content

Clinical Trials Using Histone Deacetylase Inhibitor

Review the clinical trials studying histone deacetylase inhibitor on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-23 of 23

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Status: Active
Location: 19 locations
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients with Lymphomas That Have Resisted Treatment
Status: Active
Location: 11 locations
Quisinostat for Preventing Metastasis after Treatment of High-Risk Uveal Melanoma
Status: Active
Location: 8 locations
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
Status: Active
Location: 13 locations
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Status: Active
Location: 7 locations
Total Therapy for Infants with Acute Lymphoblastic Leukemia, The TINI 2 Study
Status: Active
Location: 7 locations
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Status: Active
Location: 6 locations
Azacitidine and Romidepsin for the Treatment of Relapse or Refractory Peripheral T-cell Lymphoma
Status: Active
Location: 5 locations
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Status: Active
Location: 4 locations
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
Status: Active
Location: 3 locations
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
Status: Active
Location: 2 locations
Binimetinib plus Belinostat for the Treatment of Metastatic Uveal Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Durvalumab, and Belinostat With or Without Tremelimumab for the Treatment Metastatic or Unresectable, Locally Advanced Urothelial Carcinoma
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
PCI-24781 in Combination with Temozolomide for the Treatment of High Grade Glioma
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Intravesical Romidepsin in Combination with Durvalumab for the Treatment of Localized Muscle Invasive Bladder Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Mirdametinib and Vorinostat for the Treatment of Neurofibromatosis Type 1 and Histone H3 Lysine 27 Trimethylation-Negative Malignant Peripheral Nerve Sheath Tumors
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Status: Active
Location: See ClinicalTrials.gov
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Status: Active
Location: See ClinicalTrials.gov
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Status: Active
Location: See ClinicalTrials.gov
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Status: Active
Location: See ClinicalTrials.gov
Microdevice for In Situ Candidate Drug Screening in Skin Lesions of T-Cell Lymphoma
Status: Active
Location: 2 locations